Exai Bio announced non-small cell lung cancer data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy.
Exai Bio announced non-small cell lung cancer data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy.